Amrith Noni Completes Human Clinical Trials for Artho Plus: A Milestone in Ayurvedic Healthcare

 

Mumbai: In a groundbreaking achievement for Ayurvedic medicine, Amrith Noni has successfully completed human clinical trials for its flagship product, "Amrith Noni Artho Plus". Conducted in collaboration with Nalanda Clinserve under the stringent guidelines of CTRI-Reg India, the trials reaffirm the brand's commitment to providing scientifically validated, high-quality solutions for arthritis management.

Speaking at a press conference in Mumbai, Dr. A.K. Srinivasamurthy, Managing Director of ValYou Products Ltd., highlighted the alarming prevalence of arthritis in India, with over 210 million individuals—15% of the population—affected. "Arthritis is more widespread than cancer, AIDS, or diabetes, and stress coupled with unhealthy lifestyle changes has made it a problem for younger people as well," he noted. Emphasizing the need for safer and more effective management strategies, Dr. Srinivasamurthy underlined the significance of products like 'Amrith Noni Artho Plus' in addressing this health crisis.

'Amrith Noni', a trusted name in Ayurvedic medicine for over 15 years, has built a legacy of combining traditional wisdom with modern scientific research. The clinical trial for 'Amrith Noni Artho Plus', a double-blind and randomized study, validates its efficacy in managing osteoarthritis, rheumatoid arthritis, and gout.

Smt. Mangalambike, Managing Director of OmShree Marketing Solutions Pvt. Ltd., highlighted the product’s success: "Amrith Noni Artho Plus, developed in collaboration with Ayurvedic doctors and scientists, is India’s best-selling product for joint pain management. Over 30 lakh satisfied customers have benefited from its unique formula for knee, back, and hip pain."

Dr. K. Venkateshwaralu, Head of Clinical Research at Nalanda Clinserve, elaborated on the trial conducted in Varanasi over six months with 40 patients each for osteoarthritis, rheumatoid arthritis, and gout. Patients were assessed at two-month intervals, with the following key findings:

1. Osteoarthritis:

• Significant pain reduction and improved mobility.
• Enhanced blood calcium, magnesium levels, and bone mineral density compared to the placebo group.

2. Rheumatoid Arthritis:

• Marked reduction in inflammatory markers such as CRP, RA factor, and ESR.
• Improvements in serum immunoglobulin levels and antinuclear antibody (ANA) profiles.

3. Gout:

• Reduced pain and inflammation, improved quality of life.
• Proper kidney and liver functioning with no reported side effects.

Narayan, CEO of OmShree Marketing Solutions Pvt. Ltd., and Dr. Sandeep Benakal, an Ayurvedic expert, commended the breakthrough research, noting its potential to transform arthritis management. This milestone follows previous successes, including clinical trials for 'Amrith Noni D Plus' and cancer cell line studies with 'Canci-Care'.

Amrith Noni’s focus on rigorous scientific validation continues to bridge the gap between ancient Ayurvedic wisdom and modern healthcare, setting new standards for quality and effectiveness.